Navigation Links
ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Date:3/12/2008

SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that preliminary data from the Company's Phase 2 clinical study of ANX-510, CoFactor(R), for the treatment of advanced breast cancer has been accepted for presentation at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 30 - June 3, 2008 in Chicago, IL.

The poster presentation entitled "5,10 methylenetetrahydrofolic acid with 5-fluorouracil as treatment for advanced breast cancer in patients who failed prior treatment with anthracyclines and taxanes: A phase 2 study," is scheduled to be presented on June 2, 2008.

About ANX-510, or CoFactor

CoFactor is a folate-based biomodulator designed to replace leucovorin as the preferred method to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-FU (5-fluorouracil). Compared to leucovorin, CoFactor creates more stable binding between the active form of 5-FU and the target enzyme, thymidylate synthase. CoFactor bypasses the metabolic pathway required by leucovorin to deliver the active form of folate, potentially allowing 5-FU to work more effectively.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer and infectious disease. The Company seeks to improve the performance and commercial potential of existing treatments by addressing problems associated with these treatment regimens. More information can be found on ADVENTRX's web site at http://www.adventrx.com.
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
2. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. Genzyme Announces Presentation of New Positive Data on Carticel(R)
7. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
8. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
9. SpineSmith Partners to Present at 3rd Annual Stem Cell Summit
10. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
11. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... YORK, Feb. 17, 2011 Reportlinker.com ... report is available in its catalogue: ... 2016 - Cephalosporins, Penicillins, Macrolides and ... http://www.reportlinker.com/p0397051/Anti-Bacterials-Market-to-2016---Cephalosporins-Penicillins-Macrolides-and-Fluoroquinolones-to-Drive-the-Anti-Bacterials-Market.html ...
... Reportlinker.com announces that a new market research ... Early Stage Drug Discovery in Disease Segments ... Gene Therapies http://www.reportlinker.com/p0397053/Early-Stage-Drug-Discovery-in-Disease-Segments---Innovation-Focuses-on-Stem-Cell-Therapies-and-Gene-Therapies.html ... Segments - Innovation Focuses on Stem Cell Therapies ...
Cached Medicine Technology:Reportlinker Adds Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market 2Reportlinker Adds Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market 3Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies 2Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies 3Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies 4
(Date:7/9/2014)... Susan Wakulich was told she had an aneurysm, she figured ... her. , "I was devastated," said Wakulich, who is 56 ... this was a serious diagnosis. Then I met Dr. Bernard ... a less invasive procedure. It was something I didn,t even ... a multi-center U.S. clinical trial to evaluate the safety and ...
(Date:7/9/2014)... Fox Chase Cancer Center paint a relatively optimistic picture ... cancers that have spread to the chest wall or ... into the skin, regardless of size and whether they ... III and called "locally advanced" tumors, suggesting that ... with poor survival. Locally advanced breast cancers of this ...
(Date:7/9/2014)... release is available in French . ... in 14 year old teens, including brain structure and function, ... accuracy who will go on to develop binge drinking within ... conscientiousness, and other variables such as life events and a ... binge drinking. Whether or not the child had had ...
(Date:7/9/2014)... It may smell of flatulence and have a reputation for ... dosage, hydrogen sulfide is now being being found to offer ... to stroke, heart attacks and dementia. A new compound (AP39), ... the key to future therapies, by targeting delivery of very ... places inside cells. , Scientists in Exeter have already ...
(Date:7/9/2014)... with kidney and heart disease have raised concerns about ... However, in the first study to look closely at ... at the University of Pennsylvania report that older kidney ... and cardiovascular health as very healthy older people who ... ever increasing organ transplant waitlists, the authors of the ...
Breaking Medicine News(10 mins):Health News:New type of stent could help some brain aneurysm patients 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:What drives a child to abuse alcohol? 2Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2
... of fruit and vegetables are less likely to develop ... with chronic obstructive pulmonary disease (COPD) are smokers or ... COPD - so there must be influences that mitigate ... ,Researchers at the University of Southampton, UK, have ...
... consume wine in moderation have healthier lifestyles overall than abstainers ... well established that moderate alcohol consumption seems to confer ... of heart disease. A new study shows that it may ... produce at least some of the beneficial effects. ...
... that doctors know the power of a common heart medication ... many patients do not take the medications. Research shows the ... the risk of early death by 20 percent. However, many ... dysfunction and, therefore, do not take the drugs. A new ...
... the most widely spread cancer all over the world. ... expected to die from breast cancer this year. Researchers ... be an important factor fueling this ever-growing epidemic.// ... 25 countries that included information on breastfeeding and childbearing ...
... A commonly used antidepressant may help women who suffer ... citalopram, marketed as Celexa, may help women who have ... from the University of Pennsylvania Medical Center in Philadelphia, ... would work. Half-cycling means the medication is started 14 ...
... According to a new research, a daily dose of a ... the "bad", or LDL, cholesterol levels in young men. Functional ... supplying essential nutrients. //There has been a trend of adding ... healthier. For example, Benecol Spread is a margarine that contains ...
Cached Medicine News:Health News: Breastfeeding may decrease Breast Cancer Risk 2
... PCA Peel® formula, this peel will ... exfoliation for oilier, thicker and more ... on extremely sun damaged and thickened ... those with active/cystic acne and asphyxiated ...
It works by stimulating new growth of skin and collagen by decreasing the bond that holds dead skin cells on the surface. This allows dead cells to be removed gradually, leaving behind a layer of smo...
... LipiVage™ Fat Harvest, Wash & Transfer System ... to make fat transfer procedures simpler for ... satisfy the need for an office-based technique. ... There is no longer a need to ...
... BOTOX® Cosmetic is a simple, nonsurgical, physician-administered ... severe frown lines between the brows in ... age. It is the only treatment of ... Drug Administration (FDA). BOTOX® Cosmetic is ...
Medicine Products: